Business Context and Reporting Period
Company: Bovie Medical Corporation (Note: Metadata listed "Apyx Medical Corp," but filing text confirms "Bovie Medical Corporation")
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: Bovie is a medical device company manufacturing and marketing electrosurgical devices, including generators, accessories, saline-enhanced resection devices, and cauteries. Operations are divided into three product lines: electrosurgical products, battery-operated cauteries, and other products (nerve locators, lighting). The company sells globally through distributors to over 6,000 hospitals.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2008 |
|---|---|---|---|
| Sales (Revenue) | $6,371,371 | $20,420,272 | $20,958,672 |
| Gross Profit | $2,759,889 | $9,060,845 | $8,719,747 |
| Gross Margin | 43.3% | 44.4% | 41.6% |
| Net Income (Loss) | $(37,749) | $568,136 | $1,793,021 |
| Operating Cash Flow (9mo) | $421,093 (vs. $707,430 in 2008) | ||
| Cash & Equivalents (Sep 30, 2009) | $2,924,655 | ||
| Working Capital (Sep 30, 2009) | $10,129,867 | ||
| Debt Obligations | Line of Credit: $1,000,382; Mortgage Note: $3,906,250 (Total) |
Material Changes vs. Prior Period
- Revenue Decline: Sales for the three months ended September 30, 2009, decreased 12.7% ($924,000) compared to the same period in 2008. The nine-month period saw a 2.6% decrease.
- Drivers: Reduced capital expenditures by hospitals (down 19.5% in generators), distributor inventory reductions (down 15.3% in disposables), and a stronger U.S. dollar impacting international sales (down 8.7% in Q3).
- Profitability Shift: While the company reported a net loss of $37,749 in Q3 2009, it remained profitable for the nine-month period ($568,136). This is a significant decrease from the $1.79 million net income in the prior year's nine-month period, largely due to the absence of a $1.5 million "Gain on Cancellation of Agreement" recorded in 2008.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses increased 23.6% in Q3 and 9.6% for the nine months.
- Key Driver: A $160,000 accrual for the settlement of the Erbe USA, Inc. litigation.
- Other Drivers: Increased property taxes, electricity, and insurance costs associated with a new facility in Clearwater, Florida.
- Inventory Build-up: Inventories increased from $5.34 million (Dec 31, 2008) to $7.07 million (Sep 30, 2009), resulting in a cash outflow of $1.74 million in operating activities.
Guidance, Outlook, Risks, and Unusual Items
- Product Pipeline & Outlook: Management is focused on high-margin growth products.
- SEER & BOSS: Positive surgeon acceptance of the Saline Enhanced Electrosurgical Resection (SEER) device. A 510(k) application for the BOSS orthopedic device was filed in Q3.
- Vessel Sealing: Filed 510(k) applications for the Seal-n-Cut instrument line and ICON VS generator (market estimated at $1.0 billion).
- J-Plasma: Received FDA clearance in August 2009 for the J-Plasma technology.
- Liquidity: The company holds $2.9 million in cash and has $4.0 million of borrowing capacity available under its existing credit facility (with $1.0 million currently drawn). Management believes cash on hand and operating cash flows are sufficient for at least one year.
- Unusual Items:
- Erbe Litigation Settlement: Accrued $160,000 in Q3 2009 to settle a trade secrets lawsuit filed by Erbe USA, Inc. in 2008. The settlement includes a two-year non-solicitation agreement.
- Reclassification: Management reclassified a $1.5 million gain from the cancellation of a Boston Scientific agreement (originally recorded in 2008) from "Other Income" to "Income from Operations" for comparative purposes.
- Risks:
- Economic Conditions: Global recession and credit market constriction may cause hospitals to postpone spending and customers to aggressively manage inventories.
- Customer Concentration: The ten largest customers accounted for 73% of net revenues in the first nine months of 2009; one customer accounted for 25%.
- Foreign Currency: Results are exposed to exchange rate fluctuations, particularly the U.S. dollar vs. the Euro and British Pound.
Investor Verification Checklist
- Revenue Sustainability: Verify if the decline in generator sales and distributor inventory levels is a temporary economic effect or a structural shift in demand.
- Inventory Valuation: Assess the $7.07 million inventory balance against current sales trends to evaluate the risk of future obsolescence reserves.
- Product Launch Success: Monitor the commercial uptake of the newly cleared J-Plasma and the pending BOSS and Seal-n-Cut approvals to validate growth projections.
- Debt Covenants: Review the terms of the $1.0 million line of credit and mortgage note to ensure compliance with covenants given the recent operating loss in Q3.
- Legal Exposure: Confirm that the $160,000 Erbe settlement fully resolves the matter and that no further litigation costs are anticipated.